Type 1 Diabetes Management in the US: Epidemiologic Evidence, Trends, and Emerging Challenges
Presented by
Michael Fang, Ph.D.
We have a new date and time for the final 2025 ODP Early Stage Investigator Lecture (ESIL)! Join us on Friday, June 27*, as Dr. Michael Fang from Johns Hopkins Bloomberg School of Public Health presents on type 1 diabetes management in the United States.
ODP’s ESIL award recognizes early career prevention scientists who are poised to become future leaders in prevention research.
About the Lecture
Novel technologies and therapies have transformed the management of type 1 diabetes. Today, individuals with type 1 diabetes are living longer than ever before. However, population-based data on the burden, management, and prognosis of type 1 diabetes across the lifespan remain limited.
In this talk, Dr. Fang draws on emerging evidence from national health surveys and large electronic health record databases to describe the modern epidemiology of type 1 diabetes in the United States. His talk will highlight areas of progress and emerging challenges in type 1 diabetes management, with a focus on glycemic control, obesity, and access to new diabetes technologies.
*Please note: This is a rescheduled event. If you were registered for the original date of Dr. Fang’s lecture, you must register again for the June 27 lecture to receive the new webinar link.
Accessibility Information
This lecture will be captioned in real-time. Individuals needing reasonable accommodations should email [email protected]. Requests should be made at least 5 business days before the event.
Additional Information
Can’t be there? A recording of this lecture will be available in the weeks following the session. You can view the full archive of previous Early Stage Investigator Lectures on the Office of Disease Prevention website.
This event is open to the public and there will be an opportunity to ask questions at the end of the presentation. Please feel free to share this information widely. By registering for an ODP event, you are agreeing to our event guidelines. For more information, please contact us at [email protected].
